IBRX Profile
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies and vaccines that enhance and leverage the immune system to combat cancers and infectious diseases. The company's robust pipeline includes immunotherapy and cell therapy platforms, such as antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive T cell immune systems. These advanced platforms are designed to complement, harness, and amplify the body's natural defenses against a variety of serious health conditions.
ImmunityBio is actively advancing therapeutic agents through Phase II and Phase III clinical trials for the treatment of both liquid and solid tumors, including bladder, pancreatic, and lung cancers. The company is also targeting infectious diseases such as SARS-CoV-2 and HIV with its innovative therapies. By focusing on these critical areas, ImmunityBio aims to address significant unmet medical needs and improve patient outcomes through its cutting-edge biotechnological solutions.
In addition to its internal development efforts, ImmunityBio has established numerous collaboration and license agreements to enhance its research and development capabilities. Notable partnerships include those with the National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc. The company also holds license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. These collaborations enable ImmunityBio to access a broad range of expertise and resources, fostering innovation and accelerating the development of its therapeutic candidates.
Founded in 2014 and headquartered in San Diego, California, ImmunityBio is at the forefront of immunotherapy and cell therapy research. The company's mission is to transform the treatment landscape for cancer and infectious diseases by harnessing the power of the immune system. With a strong commitment to scientific excellence and patient care, ImmunityBio continues to pioneer new approaches in biotechnology, striving to bring effective and life-changing treatments to patients worldwide.
|
